Huntington’s disease

#Clinical trial #Huntington's disease #Regulatory #uniQure

From the Editor: Terms and Conditions

The recent report that pharmaceutical company uniQure’s data from its Phase I/II studies provide insufficient evidence for the approval of its investigational gene therapy drug for Huntington’s disease (HD) are a major blow for patients.  Huntington’s disease is a rare genetic disorder that can affect around 5-10 people per… Read More

#Exclusive Content #Opinion

#Advanced Therapies #FDA #Gene therapy #Huntington's disease #uniQure

Investors file lawsuit against uniQure following FDA ruling

The US Food and Drug Administration (FDA) has ruled that data from Phase I/II studies are insufficient evidence to approve the marketing authorisation for uniQure’s AMT-130, an investigational gene therapy for Huntington’s disease (HD).   In response, investors have issued a class action securities lawsuit to recover losses. Read More

#Business & Investment #News #Trending News

Neuronal inclusions in Huntington’s disease
#Genetic diseases #Harness Therapeutics #Huntington's disease #Neuroscience

Harness Therapeutics nominates drug candidate for Huntington’s

Harness Therapeutics has announced the nomination of HRN001 as its lead drug candidate for Huntington’s disease (HD).  The company has also formed a clinical advisory board to support the programme’s advancement towards clinical evaluation.  Despite significant advances in understanding HD disease biology, there are currently… Read More

#News

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

DDW Highlights: 13 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a new report found breast cancer was the world’s most studied disease… Read More

#Podcasts

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

This week in Drug Discovery (5 – 9 January) 

News round-up for 5 – 9 January by Bruno Quinney, Content Team at DDW.  This week in DDW, a new report finds breast cancer is the world’s most studied disease for the fifth year running. That same report predicts obesity to break into the top five, with weight loss a key theme across… Read More

#News

Neuronal inclusions in Huntington’s disease
#Biotech #Huntington's disease #LoQus23 Therapeutics

Groundbreaking Huntington’s disease drug set for development 

Biotechnology company LoQus23 Therapeutics has nominated its drug candidate LQT-23 for development as a treatment for Huntington’s Disease (HD).  LQT-23 is a first-in-class oral drug candidate which has shown potential to slow or stop the progression of HD. The candidate works as an allosteric small molecule inhibitor… Read More

#News

Gene therapy
#Gene editing #Gene therapy #Genetic diseases #Huntington's disease #uniQure

Trial shows slowing of Huntington’s progression for the first time

A global clinical trial for a new Huntington’s disease gene therapy has posted positive results, including 75% less progression of the disease.  AMT-130 is the first gene therapy to be tested in people with Huntington’s. This is also the first time a drug trial has reported continuing,… Read More

#News #Trending News

Neuronal inclusions in Huntington’s disease
#Biotech #Huntington's disease #Orphan drugs

EMA positive towards unique Huntington’s drug

The European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion for granting orphan drug designation (ODD) to the drug SOM3355 for the treatment of Huntington’s disease.  The decision made by the EMA’s Committee for Orphan Medical Product (COMP) recognises an ongoing… Read More

#News

#Genetic diseases #Huntington's disease #Neurodegenerative disorders #Neuroscience

Tipping point in Huntington’s disease research

Jan Thirkettle, CEO of Harness Therapeutics, looks at the emerging opportunities for drug discovery and development for Huntington’s disease. Huntington’s disease (HD) represents one of medicine’s most significant unmet needs, affecting approximately 10 in 100,000 people, with over 200,000 people at risk of inheriting the disease in the US alone. Read More

#Exclusive Content

Neuronal inclusions in Huntington’s disease
#Financing #Huntington's disease #LoQus23 Therapeutics #Neurodegenerative disorders

New therapy for Huntington’s disease gets £35 million boost

Biotechnology company LoQus23 Therapeutics has closed its £35 million (c.$43 million) Series A financing. The financing round was led by Forbion, alongside existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). Forbion General Partner Rogier Rooswinkel will join LoQus23’s Board of… Read More

#Business & Investment #News

Neuronal inclusions in Huntington’s disease
#Huntington's disease #Phase II trial #PTC Therapeutics #Trial data

Positive interim data for Huntington’s disease therapy

PTC Therapeutics has shared interim data from the 12-week portion of the PIVOT-HD Phase II study of PTC518 in Huntington’s disease (HD) patients. The study demonstrated dose-dependent lowering of Huntingtin (HTT) protein levels in peripheral blood cells, reaching a mean 30% reduction in mutant HTT levels… Read More

#News

#App note #Genetic profiling #Human disease models #Huntington's disease #Phenotyping

Using disease models to accelerate Huntington’s disease research

Currently, no effective cure or treatment for Huntington’s disease exists. To accelerate Huntington’s disease research and drug discovery, researchers need access to physiologically relevant human disease models that recapitulate patient phenotypes, in combination with more advanced methods to understand the underlying mechanisms of the disease. Download this… Read More

#News

#App note #Genetic profiling #Human disease models #Huntington's disease #Phenotyping

Characterising the phenotype of an isogenic, human iPSC-derived Huntington’s disease model by MEA

Currently, no effective cure or treatment for Huntington’s disease exists. To accelerate Huntington’s disease research and drug discovery, researchers need access to physiologically relevant human disease models that recapitulate patient phenotypes, in combination with more advanced methods to understand the underlying mechanisms of the disease. In this App Note you… Read More

#App Notes #Intelligence #Resources

#Drug discovery #EMA #Funding #Huntington's disease #Monkeypox #Start-ups

This week in drug discovery (21 – 25 August)

News round-up for 21-25 August by DDW Editor Reece Armstrong A treatment for Monkeypox, spider venom for drug discovery and funding for international start-ups are some of the stories in this week’s news round-up. Covid researchers launch Monkeypox study   A new study investigating a potential treatment… Read More

#News

#Antibodies #Drug development #Drug discovery #Huntington's disease

Collaboration to develop landmark novel antibody therapy for Huntington’s

Alchemab, a biotech company harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support its collaboration with Medicines Discovery Catapult and the development of a novel disease-modifying antibody therapy for Huntington’s disease. Using its novel approach, Alchemab has… Read More

#News